JP2024541048A5 - - Google Patents
Info
- Publication number
- JP2024541048A5 JP2024541048A5 JP2024525790A JP2024525790A JP2024541048A5 JP 2024541048 A5 JP2024541048 A5 JP 2024541048A5 JP 2024525790 A JP2024525790 A JP 2024525790A JP 2024525790 A JP2024525790 A JP 2024525790A JP 2024541048 A5 JP2024541048 A5 JP 2024541048A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- sequence
- sequence number
- antigen
- kabat numbering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021128208 | 2021-11-02 | ||
| CNPCT/CN2021/128208 | 2021-11-02 | ||
| PCT/CN2022/127036 WO2023078113A1 (en) | 2021-11-02 | 2022-10-24 | Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024541048A JP2024541048A (ja) | 2024-11-06 |
| JP2024541048A5 true JP2024541048A5 (https=) | 2025-10-30 |
Family
ID=86240641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525790A Pending JP2024541048A (ja) | 2021-11-02 | 2022-10-24 | 抗ｃｄ１２２抗体、抗ｃｄ１３２抗体、及び関連する二重特異性結合性タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250002594A1 (https=) |
| EP (1) | EP4426742A4 (https=) |
| JP (1) | JP2024541048A (https=) |
| CN (1) | CN118251416A (https=) |
| CA (1) | CA3236138A1 (https=) |
| TW (1) | TW202334219A (https=) |
| WO (1) | WO2023078113A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116789828B (zh) * | 2023-05-31 | 2023-11-17 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 一种抗cd132的单克隆抗体及其应用 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| CN117886940B (zh) * | 2024-01-19 | 2024-11-19 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 人源化抗人cd132单克隆抗体及其应用 |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026033139A1 (en) | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560994B1 (en) * | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| US10519251B2 (en) * | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| PT3328894T (pt) * | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| EP3707162A1 (en) * | 2017-11-10 | 2020-09-16 | Agency for Science, Technology and Research | Il2rbeta/common gamma chain antibodies |
| TW202031683A (zh) * | 2018-11-09 | 2020-09-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| WO2020160242A1 (en) * | 2019-02-01 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
-
2022
- 2022-10-24 JP JP2024525790A patent/JP2024541048A/ja active Pending
- 2022-10-24 US US18/706,263 patent/US20250002594A1/en active Pending
- 2022-10-24 WO PCT/CN2022/127036 patent/WO2023078113A1/en not_active Ceased
- 2022-10-24 CN CN202280072965.4A patent/CN118251416A/zh active Pending
- 2022-10-24 CA CA3236138A patent/CA3236138A1/en active Pending
- 2022-10-24 EP EP22889138.8A patent/EP4426742A4/en active Pending
- 2022-11-01 TW TW111141612A patent/TW202334219A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024541048A5 (https=) | ||
| CN113015749B (zh) | 靶向cd3的抗体、双特异性抗体及其用途 | |
| CN114502591B (zh) | 靶向bcma的抗体、双特异性抗体及其用途 | |
| JP2023538945A5 (https=) | ||
| JP7840955B2 (ja) | 抗ヒトｂ７－ｈ３抗体及びその利用 | |
| TW202334219A (zh) | 抗ｃｄ１２２抗體、抗ｃｄ１３２抗體及相關的雙特異性結合蛋白 | |
| JP7728595B2 (ja) | 二重特異性抗体及びその用途 | |
| JP7766672B2 (ja) | ＴＧＦ－β ＲＩＩ突然変異体及びその融合タンパク質 | |
| JP2022527151A5 (https=) | ||
| CN114206931A (zh) | 抗pd-1抗体及其用途 | |
| CN111171155A (zh) | 抗cd3和cd123双特异性抗体及其用途 | |
| WO2023040945A1 (zh) | 特异性结合pd-1的蛋白及其医药用途 | |
| TW202128765A (zh) | 一種雙特異性抗體 | |
| JP2023518225A5 (https=) | ||
| JP2023547662A5 (https=) | ||
| WO2024017326A1 (zh) | 抗gprc5d纳米抗体及其应用 | |
| CN110172100B (zh) | 抗人cd3e抗体及其用途 | |
| IL312060A (en) | Bispecific CD16A binders | |
| CN121263447A (zh) | Trop2抗体 | |
| CN121175340A (zh) | 抗pd-1-抗vegf的双特异性抗体、其药物组合物及其用途 | |
| CN113527491B (zh) | 人源化抗体、嵌合抗原受体、核酸、载体、细胞及应用 | |
| CN115073596B (zh) | 一种人源化Claudin18.2抗体及其应用 | |
| JP2024509369A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| TW202542192A (zh) | 靶向ｃｄ３的抗體及其應用 | |
| HK40070151B (en) | Bispecific antibody and use thereof |